Navitoclax is a small-molecule inhibitor of the Bcl-2 family (i.e., BCL2, BCL2L1, BCL2L2) of antiapoptotic proteins with demonstrated activity in preclinical ovarian cancer models, including an ex vivo model of 25 high-grade serous ovarian cancers [19]. Here, BCL2 is linked to ovarian carcinoma.